Posted by Michael Wonder on 15 Apr 2019
Big pharma might cut research, delay new drugs if Pharmacare means more generics
14 April 2019 - Pharmacare is shaping up as a key campaign issue in the October election, particularly for the Liberals.
Brand-name drug companies could put off introducing new medicine in Canada and scale back research here if the country makes a major shift to cheaper generic alternatives under a national Pharmacare plan, according to an internal federal analysis.
The concerns were included last year in a briefing document for federal Finance Minister Bill Morneau that explored the feasibility and costs of a Pharmacare program.
